Jul 22, 2025
SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study
Jul 08, 2025
Independent Meta-Analysis Shows SkylineDx's Merlin CP-GEP Assay Accurately Stratifies Patients for Sentinel Lymph Node Biopsy Selection
Jun 12, 2025
Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling
Jun 02, 2025
SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and Neck Melanoma Without Sentinel lymph node Biopsy at ASCO 2025
Mar 28, 2025
SkylineDx presents landmark findings from the largest prospective multicenter melanoma GEP trial at SSO 2025
Mar 12, 2025
SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST
Dec 07, 2024
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
Oct 24, 2024
Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care
Oct 13, 2024
SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at 21st International Congress of the Society for Melanoma Research
Oct 11, 2024
SkylineDx Announces Presentation of New Data Highlighting the Predictive Power of the CP-GEP Merlin Test for T1a Cutaneous Melanoma Patients at the 21st International Congress of the Society for Melanoma Research
Oct 08, 2024
SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
May 30, 2024
SkylineDx's Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence
Apr 05, 2024
Independent European data on CP-GEP model in Stratifying Melanoma Patients for Long Term Survival
Feb 23, 2021
SkylineDx, Oncode Institute and Utrecht Holdings sign license agreement for innovative algorithm RAINFOREST
Feb 18, 2021
SkylineDx achieves new milestone with ISO 13485:2016 certification
Sep 10, 2020
SkylineDx inks collaboration agreement with Imperial College London and UCSD on diagnostic test Kawasaki Disease
Aug 26, 2020
How the Dutch resume elective surgery in melanoma after COVID delays
Mar 17, 2020
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
Sep 02, 2019
Dutch Company Receives EUR20 Million for Skin Cancer Diagnostic Test
Jan 31, 2018
SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma